{"disease":{"id":"carcinoma-non-small-cell-lung-nsclc","name":"carcinoma non small cell lung nsclc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06758401","title":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07135882","title":"Primary Radiotherapy In MEtastatic Lung Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":420,"lead_sponsor_name":"Trans Tasman Radiation Oncology Group","has_results":false},{"nct_id":"NCT06885424","title":"A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07277413","title":"A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT06476808","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06895031","title":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Guangzhou JOYO Pharma Co., Ltd","has_results":false},{"nct_id":"NCT06833229","title":"Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Centre Antoine Lacassagne","has_results":false},{"nct_id":"NCT06595498","title":"Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":130,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT06362369","title":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"7 Hills Pharma, LLC","has_results":false},{"nct_id":"NCT07489066","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02771626","title":"Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":118,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":true},{"nct_id":"NCT05241873","title":"(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT02392507","title":"A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04424641","title":"A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":48,"lead_sponsor_name":"Genmab","has_results":true},{"nct_id":"NCT07408635","title":"IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT02905591","title":"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Joseph J. Cullen, MD, FACS","has_results":false},{"nct_id":"NCT06693336","title":"An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"ToLymph Inc.","has_results":false},{"nct_id":"NCT03652077","title":"A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05837767","title":"A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue","phase":"NA","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03538028","title":"A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Incyte Biosciences International Sàrl","has_results":false},{"nct_id":"NCT01666353","title":"PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT05068102","title":"A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT02698176","title":"A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03128008","title":"Locally Advanced NSCLC Hyperfractionated RT","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT06841874","title":"Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}